Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Three general questions:
Doesn’t anyone know say out of 1,000 cig smokers and tobacco chewers what the ratio is of tobacco chewers?
What’s the market for Skoll, snuff, loose leaf tobacco, or whatever annually?
Is this patent even worthwhile pursuing?
Yes, the botanical initiative is well worth following. I felt for some time this is a big issue and looking forward to its progression. Also agree with the bio related partner comments.
I don’t know what to make of the dewormer story at this time :)
Yeah okay Wolf! Let’s see that CV 10K
Agree, JT took the correct path on this issue! No need to mislead shareholders otherwise!
You right on this! If the fee was paid Jan 20th, this was news worthy to shareholders well before yesterday.
Interesting thread and yes, how would the release be known when no one else does?
Three months? I was thinking maybe a few weeks which is still too long.
I think Jared’s comments on the CC regarding below were most interesting!
“On the Q2 2022 earnings call, we discussed that we were exploring an investigational new drug pathway through the FDA. On our Q3 call, we further discussed the reasons why and how we could do this on a capital-free basis through potential partnering. Charlotte's Web's unique advantage lies in its intellectual property, including 7 hemp patents, safety and toxicology studies, GMP quality control systems and a state-of-the-art manufacturing and distribution facility.
Our IP can be licensed into a biotech partnership leveraging a clinical science and regulatory team to seek an IND and navigate clinical trials to, ultimately, create a botanical drug. The CBD market is estimated at $5 billion today with approximately $1 billion from Epidiolex, the only FDA-approved CBD drug to date. By partnering on an IND path, we provide risk-mitigated upside to our shareholders by unlocking IP value created since the inception of the company and leveraging our core strengths.
We are progressing with speed on this strategy, and we look forward to updating deeper as this leg unfolds.”
Todays PR was timed for sure. It’s how the game works. However, can’t put too much on the last year as it sucked for the entire space.
If the company makes the case they can capitalize on the patent, may be a decent short term trade but I don’t see it at this point.
You know when the CC is scheduled?
While no analysts have covered CV since last year, interested in forward statements from the company and compare to what we read here.
I realize the statements made on the funding requirements. That’s my point!
Patents are good. However, someone give a realistic response how this IP gets gets moved forward. There may be a great answer to this but no one seems to answer this question. A Nordic JV won’t do it.
What expertise would Nordic bring to the table with getting synthetic CBD through trials?
Not specific to the 007 patent, a number of companies have patents in development related to synthetic CBD and variations thereof for a number of other uses. One common theme is the molecules are extremely complex and the significant spend necessary to move initiatives forward. It doesn’t take a scientist to see there are challenges for all in this area. Short of the sale of the IP, how does CV fund the 007 initiative?
This is a good thing Thomas. However, short of selling the IP, tell us where the funding comes from to get this past pre-clinical stage? Let’s put off the phase trials and those costs for now. In the best case, it will take plenty of time/money to move this forward.
Secondly, why isn’t CV telling investors/potential investors how this will go forward?
The number comes from estimated brands circulating in the market - I’ve seen 3000 to 4000. Whatever, the number is very significant regardless.
It’s going to take plenty of dough and some time to get the 007 using synthetic CBD thought trials. Tell us where the $$ comes from? Already like 8 or 9 years into the patent life. A lot time lost.
a JV with Nordic will cure all ills with CVSI? Unfortunately, it’s just not very interesting a move. This will not separate CV from the other 4000 sellers.
CV’s potential differentiator was 007 but wasting 8 years and even not in pre- clinical essentially puts this to rest.
Agree, the ISO issuance alone means little if anything.
I don’t see it happening anytime soon but your right never know.
It’s the option grant I suppose. Neutral move at this time. Now if he bought 2.5 mill shares, that’s much more interesting.
Are you suggesting CW sells to Tilray?
The granting of ISO’s is not a good or bad sign. Certainly doesn’t prove anything.
Yep! However, have to agree with some here, this will most likely trade a bit lower.
Great find DY! I like the IND reference and something I’ve been trying to find out more on for some time.
This is a cv board. Silly post. Tells us why cv is a buy?
Thomas? Bar Charts doesn’t discuss the story. Who’s covering this stock?
Please post who’s indicating but rec. interested to see another perspective on CV.
Disagreement is what makes the markets work Thomas.
If we see positive developments that are truly accretive, then hats off to you, Wolf, and others. If you gents make $$ in this, that’s great.
Sure, we’ve been reading about mergers, joint ventures, or whatever as it relates to CVSI for like for ever it seems. Still trades at 4.5 cents which tells us no one cares.
For those reading the Nordic partnership comments, it won’t change the fortunes of CV regardless. If it happens, don’t see it hurting CV but it won’t be the impetus for a turnaround. It’s really that simple.
Detractors, let’s not deflect bringing CW into the issue. We all know they have their own issues.
I don’t think every company on your list exclusively sells CBD so the sales numbers may be misleading.
Curious of the quality of CBD Warehouse products. Not a answer one way or another but their packaging does look a bit cheesy.
Actually, things are looking better! So much more happening with CW than CV!
Unlike CW, CV Sciences is sorely any lacking science.
Yoda posting the good stuff yet again. I like today’s PR! JT has his foot on the gas pedal attacking CBD from the scientific side. I believe they are on to things. This is where the money will be made in cannabinols. I friggin love it!
Dowling would be salivating if a company the size of BAT put 56 milly into CV’s coffers. Instead he had to settle with ceding control to a bottom level PE firm for 700k!!!
Watch what happens in the next couple years. CW is and will remain best in breed!
You understand now right?
No offense but you may be a good replacement for our babbling VP :)
Just busting! Your post is spot on.
Same issues exist in the US. Also, seems the piece is more about companies located there. Is product sales there are not productive for companies shipping there, they can just stop shipping there.
You make it seem as though CV not there was a calculated move which is highly doubtful.
Regardless, both CW and CV most likely will see sales declines in Q4. Its a waiting game at this point.
Yeah, okay right!
HA! using CA $$ for the high and US for the low. Classic!
CV 9$ high to 1.8 cents low! Do that math!
Of the many things CW has over its nominal competitor, very important ones are CASH and strategy. Our nominal competitor has neither!
Yep, there’s no volume in the stock. This tells a bigger story than anyone on this board can. Window dressing trades and nothing more!
All kinds of deals rumored and volume drying up!
Let’s see. Which one is more reliable?
YEP!
Very little $$ has been made overall the last couple months in this symbol. The volume just isn’t there.
We’ve been reading the rumor mill run a muck for the last year on this board. Nothing has materialized. Deflecting to CW doesn’t cover up CVSI’s lack of strategy.